CORRECTION

Correction to: Asthma and Chronic Obstructive Pulmonary Disease Overlap According to the Japanese Respiratory Society Diagnostic Criteria: The Prospective, Observational ACO Japan Cohort Study

Shu Hashimoto · Ryoko Sorimachi · Tatsunori Jinnai · Masakazu Ichinose

Published online: January 6, 2022
© Springer Healthcare Ltd., part of Springer Nature 2021

Correction to: Adv Ther (2021) 38:1168–1184
<https://doi.org/10.1007/s12325-020-01573-x>

In the original article, Tables 5 and 6 were published incorrectly. The correct Tables 5 and 6 are given below.

In addition, there is an error in the discussion section. The second paragraph of the discussion section currently reads: “The data obtained at registration showed that ICS use

was relatively common in Japanese ACO patients (76.5%) compared with 36.3% of non-ACO patients.” This sentence should read: “The data obtained at registration showed that ICS use was relatively common in Japanese ACO patients (74.3%) compared with 35.6% of non-ACO patients.”

The original article can be found online at <https://doi.org/10.1007/s12325-020-01573-x>.

S. Hashimoto (✉)
Nihon University, Itabashi-ku, Tokyo, Japan
e-mail: hashimoto.shu@nihon-u.ac.jp

S. Hashimoto
Hibiya Kokusai Clinic, Chiyoda-ku, Tokyo, Japan

R. Sorimachi · T. Jinnai
Medical Department, AstraZeneca K.K., Kita-ku, Osaka, Japan

M. Ichinose (✉)
Academic Center of Osaki Citizen Hospital, Miyagi, Japan
e-mail: ichinose@h-osaki.jp

Table 5 Characteristics of patients with or without ACO at registration among those who had the data necessary for ACO diagnosis

	Patients with the data necessary for ACO diagnosis			<i>p</i> value (ACO vs non-ACO)
	All (<i>n</i> = 396)	ACO (<i>n</i> = 101)	Non-ACO (<i>n</i> = 295)	
Sex, male, <i>n</i> (%)	353 (89.1)	90 (89.1)	263 (89.2)	0.990
Age, years, mean (SD)	73.2 (8.0)	71.5 (9.6)	73.8 (7.3)	0.025
BMI, kg/m ² , mean (SD)	23.0 (3.4)	23.0 (3.1)	23.0 (3.5)	0.869
Smoking status, <i>n</i> (%)				
Current smoker	42 (10.6)	6 (5.9)	36 (12.2)	0.108
Never smoker	4 (1.0)	2 (2.0)	2 (0.7)	
Ex-smoker	350 (88.4)	93 (92.1)	257 (87.1)	
Smoking history (pack-years)	<i>n</i> = 392	<i>n</i> = 99	<i>n</i> = 293	
Mean (SD)	55.1 (35.8)	57.7 (40.7)	54.2 (34.1)	0.441
Duration of COPD, years	<i>n</i> = 390	<i>n</i> = 99	<i>n</i> = 291	
Mean (SD)	5.3 (5.4)	5.3 (4.6)	5.3 (5.7)	0.997
GOLD stage, <i>n</i> (%)				
I	125 (31.6)	30 (29.7)	95 (32.2)	0.207
II	194 (49.0)	54 (53.5)	140 (47.5)	
III	59 (14.9)	16 (15.8)	43 (14.6)	
IV	18 (4.5)	1 (1.0)	17 (5.8)	
Complication/comorbidity, <i>n</i> (%)				
Asthma (based on physician's diagnosis)	177 (44.7)	68 (67.3)	109 (36.9)	< 0.001
Age at onset < 40 years	<i>n</i> = 175	<i>n</i> = 67	<i>n</i> = 108	
	24 (13.7)	23 (34.3)	1 (0.9)	< 0.001
Age at onset ≥ 40 years	<i>n</i> = 175	<i>n</i> = 67	<i>n</i> = 108	
	151 (86.3)	44 (65.7)	107 (99.1)	< 0.001
Allergic rhinitis	57 (14.4)	37 (36.6)	20 (6.8)	
Heart failure	45 (11.4)	3 (3.0)	42 (14.2)	0.002
Diabetes	58 (14.6)	15 (14.9)	43 (14.6)	0.946
Respiratory medication at baseline, <i>n</i> (%)	<i>n</i> = 396	<i>n</i> = 101	<i>n</i> = 295	
ICS (monotherapy or any combinations)	180 (45.5)	75 (74.3)	105 (35.6)	< 0.001
ICS monotherapy	4 (1.0)	3 (3.0)	1 (0.3)	0.053
LAMA monotherapy	44 (11.1)	10 (9.9)	34 (11.5)	0.654
LABA monotherapy	20 (5.1)	1 (1.0)	19 (6.4)	0.031
LAMA and LABA ^a	138 (34.8)	11 (10.9)	127 (43.1)	< 0.001
ICS and LABA ^a	65 (16.4)	22 (21.8)	43 (14.6)	0.092

Table 5 continued

	Patients with the data necessary for ACO diagnosis			<i>p</i> value (ACO vs non-ACO)
	All (<i>n</i> = 396)	ACO (<i>n</i> = 101)	Non-ACO (<i>n</i> = 295)	
ICS and LAMA	4 (1.0)	2 (2.0)	2 (0.7)	0.270
ICS, LAMA, and LABA ^a	107 (27.0)	48 (47.5)	59 (20.0)	< 0.001
Symptoms based on interview				
Presence of variable symptoms, <i>n</i> (%)	96 (24.2)	67 (66.3)	29 (9.8)	< 0.001
Presence of paroxysmal symptoms, <i>n</i> (%)	<i>n</i> = 387	<i>n</i> = 95	<i>n</i> = 292	
	90 (23.3)	57 (60.0)	33 (11.3)	< 0.001
Questionnaire				
CAT	<i>n</i> = 395	<i>n</i> = 101	<i>n</i> = 294	
Mean (SD)	10.3 (7.0)	10.7 (7.8)	10.1 (6.7)	0.492
mMRC	<i>n</i> = 395	<i>n</i> = 101	<i>n</i> = 294	
Mean (SD)	1.0 (1.0)	1.0 (1.0)	1.1 (1.0)	0.523
ACQ	<i>n</i> = 394	<i>n</i> = 101	<i>n</i> = 293	
Mean (SD)	0.5 (0.8)	0.9 (1.0)	0.4 (0.6)	< 0.001

ACO asthma-COPD overlap, ACQ asthma control questionnaire, BMI body mass index, CAT COPD assessment test, COPD chronic obstructive pulmonary disease, GOLD Global Initiative for Chronic Obstructive Lung Disease, ICS inhaled corticosteroids, LABA long-acting β_2 -agonist, LAMA long-acting muscarinic antagonist, mMRC modified Medical Research Council questionnaire, SD standard deviation

^aIncluding any combinations of separate and combined inhalers

Table 6 Biomarker and lung function measurements of patients with or without ACO at registration among those who had the data necessary for ACO diagnosis

	Patients with the data necessary for ACO diagnosis			<i>p</i> value
	All (<i>n</i> = 396)	ACO (<i>n</i> = 101)	Non-ACO (<i>n</i> = 295)	(ACO vs non-ACO)
Biomarkers				
FeNO, ppb	<i>n</i> = 355	<i>n</i> = 86	<i>n</i> = 269	
Mean (SD)	27.4 (23.5)	47.8 (35.5)	20.9 (12.5)	< 0.001
Median	22.0	41.5	20.0	
FeNO > 35 ppb, <i>n</i> (%)	75 (21.1)	59 (68.6)	16 (5.9)	< 0.001
Peripheral eosinophils absolute count, cells/μL	<i>n</i> = 370	<i>n</i> = 92	<i>n</i> = 278	
Mean (SD)	241.1 (277.9)	392.8 (472.2)	190.9 (139.4)	< 0.001
Median	176.0	289.5	160.5	
Eosinophil ratio, %	<i>n</i> = 370	<i>n</i> = 92	<i>n</i> = 278	

Table 6 continued

	Patients with the data necessary for ACO diagnosis			<i>p</i> value (ACO vs non-ACO)
	All (<i>n</i> = 396)	ACO (<i>n</i> = 101)	Non-ACO (<i>n</i> = 295)	
Mean (SD)	3.8 (3.8)	5.9 (6.0)	3.1 (2.3)	< 0.001
Total IgE, IU/mL	<i>n</i> = 278	<i>n</i> = 75	<i>n</i> = 203	
Mean (SD)	415.1 (837.9)	833.2 (1330.2)	260.6 (475.1)	< 0.001
Median	133.5	398.0	92.0	
Presence of ≥ 1 positive allergen detected in the specific IgE exam, <i>n</i> (%)	<i>n</i> = 147 64 (43.5)	<i>n</i> = 39 24 (61.5)	<i>n</i> = 108 40 (37.0)	0.008
Lung function				
Post-bronchodilator FEV ₁ /FVC%, mean (SD)	53.1 (12.0)	53.3 (9.9)	53.0 (12.7)	0.792
Post-bronchodilator %FEV ₁ predicted, mean (SD)	68.1 (21.7)	69.2 (20.6)	67.7 (22.1)	0.545
FEV ₁ reversibility (change in FEV ₁ > 12% and > 200 mL)	<i>n</i> = 239	<i>n</i> = 61	<i>n</i> = 178	
Yes, <i>n</i> (%)	14 (5.9)	8 (13.1)	6 (3.4)	0.010
Presence of emphysema on CT, <i>n</i> (%)	<i>n</i> = 311 265 (85.2)	<i>n</i> = 80 64 (80.0)	<i>n</i> = 231 201 (87.0)	0.128
%D _{LCO} < 80% or %D _{LCO} / <i>V</i> _A < 80%, <i>n</i> (%)	<i>n</i> = 183 130 (71.0)	<i>n</i> = 53 31 (58.5)	<i>n</i> = 130 99 (76.2)	0.017

ACO asthma-COPD overlap, CT computed tomography, *D*_{LCO} diffusion capacity for carbon monoxide, *FeNO* fractional exhaled nitric oxide, *FEV*₁ forced expiratory volume in one second, *FVC* forced vital capacity, *Ig* immunoglobulin, *SD* standard deviation, *V*_A alveolar volume